We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AVEO Gets Complete Response Letter for Tivozanib
AVEO Gets Complete Response Letter for Tivozanib
June 10, 2013
The FDA has rejected AVEO’s kidney cancer candidate tivozanib in line with an advisory committee’s recent recommendations.